Prof. Dr. Emma Morris is the director of the NIHR UCLH/UCL Biomedical Research Centre Inflammation, Immunity and Immunotherapeutics research programme and Co-Chair of the UCL Cell, Gene and Regenerative Medicine Therapeutic Innovation Network.
Her research group is interested in altering both the specificity and the function of gene-modified immune cells. These immune cells can then be used to treat cancer, infection or immune system disorders. Her research team investigates basic cellular and molecular mechanisms that influence how immune cells behave and how they recognise that cancer cells are different to normal cells, or why, in some cases, this does not occur.
Her clinical interest are in the field of allogeneic haematopoietic stem cell transplantation and gene therapy.
She is in Clinical Medicine at the University of Cambridge before specialising in Haemato-oncology and allogeneic bone marrow transplantation. I am currently a Transplant Consultant at University College London Hospital NHS FT and the Royal Free London NHS FT. In receive research funding from the Bloodwise, MRC, CRUK Experimental Cancer Medicine Centre and the Wellcome Trust.
She graduated from the University of Cambridge in 1992 and subsequently trained at the Royal London Hospital, Guys Hospital and UCLH. I undertook a PhD in stem cell biology at the University of Cambridge prior to completing her postgraduate specialist training.
Her research group focuses on novel aspects of immune therapies for haematological malignancies and inherited immune deficiencies, predominantly cellular and gene therapy and more recently, gene editing.